119 related articles for article (PubMed ID: 8857669)
21. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
Yasuda H
Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
[TBL] [Abstract][Full Text] [Related]
22. Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections.
Duray PH; Palazzo J; Gown AM; Ohuchi N
Cancer; 1988 Jun; 61(12):2460-8. PubMed ID: 3365669
[TBL] [Abstract][Full Text] [Related]
23. Detection of mouse tyrosinase with a monoclonal antibody MAT-1 against human tyrosinase.
Suzuki S; Takimoto H; Masui S; Kato T; Shibata K; Tomita Y; Shibahara S; Nakano H
Pigment Cell Res; 1996 Dec; 9(6):298-303. PubMed ID: 9125753
[TBL] [Abstract][Full Text] [Related]
24. [Immunohistochemical demonstration of tyrosinase 4 in normal skin and melanocytic tumors].
Kageshita T; Ono T; Arao T; Tomita Y
Nihon Hifuka Gakkai Zasshi; 1987 May; 97(6):685-90. PubMed ID: 3114516
[No Abstract] [Full Text] [Related]
25. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
26. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.
Trefzer U; Rietz N; Chen Y; Audring H; Herberth G; Siegel P; Reinke S; Königer P; Wu S; Ma J; Liu Y; Wang H; Sterry W; Guo Y
Arch Dermatol Res; 2000 Dec; 292(12):583-9. PubMed ID: 11214818
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of ras oncogene products among the types of human melanomas and melanocytic nevi.
Yasuda H; Kobayashi H; Ohkawara A; Kuzumaki N
J Invest Dermatol; 1989 Jul; 93(1):54-9. PubMed ID: 2664010
[TBL] [Abstract][Full Text] [Related]
28. Complementary expression of melanosomal antigens and constant expression of pigment-independent antigen during the evolution of melanocytic tumours.
Takahashi H; Parsons PG; Favier D; McEwan M; Strutton GM; Akutsu Y; Jimbow K
Virchows Arch A Pathol Anat Histopathol; 1990; 416(6):513-9. PubMed ID: 2110698
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibody against a melanosomal protein in melanotic and amelanotic human melanoma cells.
McEwan M; Parsons PG; Moss DJ; Burrows S; Stenzel D; Bishop CJ; Strutton GM
Pigment Cell Res; 1989; 2(1):1-7. PubMed ID: 2470076
[TBL] [Abstract][Full Text] [Related]
31. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma.
Fetsch PA; Riker AI; Marincola FM; Abati A
Cancer; 2000 Aug; 90(4):252-7. PubMed ID: 10966567
[TBL] [Abstract][Full Text] [Related]
32. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
Takahashi H; Strutton GM; Parsons PG
Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
[TBL] [Abstract][Full Text] [Related]
33. Development and characterization of a mouse monoclonal antibody, MoAb HMSA-1, against a melanosomal fraction of human malignant melanoma.
Akutsu Y; Jimbow K
Cancer Res; 1986 Jun; 46(6):2904-11. PubMed ID: 3516387
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
[TBL] [Abstract][Full Text] [Related]
35. Redefining the skin's pigmentary system with a novel tyrosinase assay.
Han R; Baden HP; Brissette JL; Weiner L
Pigment Cell Res; 2002 Aug; 15(4):290-7. PubMed ID: 12100495
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections.
Chadburn A; Husain S; Knowles DM
Hum Pathol; 1992 Aug; 23(8):940-7. PubMed ID: 1353748
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A.
Ramos-Vara JA; Miller MA
Vet Pathol; 2011 Mar; 48(2):443-50. PubMed ID: 20858741
[TBL] [Abstract][Full Text] [Related]
38. Primary mucosal malignant melanoma: an immunohistochemical study of 12 cases with comparison to cutaneous and metastatic melanomas.
Fitzgibbons PL; Chaurushiya PS; Nichols PW; Chandrasoma PT; Martin SE
Hum Pathol; 1989 Mar; 20(3):269-72. PubMed ID: 2722176
[TBL] [Abstract][Full Text] [Related]
39. Isolation and characterization of tyrosinase inhibitors and their differential action on melanogenic subcellular compartments in amelanotic and melanomas.
Imokawa G; Mishima Y
Br J Dermatol; 1980 Dec; 103(6):625-33. PubMed ID: 6779849
[TBL] [Abstract][Full Text] [Related]
40. Production of melanocyte-specific antibodies to human melanosomal proteins: expression patterns in normal human skin and in cutaneous pigmented lesions.
Virador V; Matsunaga N; Matsunaga J; Valencia J; Oldham RJ; Kameyama K; Peck GL; Ferrans VJ; Vieira WD; Abdel-Malek ZA; Hearing VJ
Pigment Cell Res; 2001 Aug; 14(4):289-97. PubMed ID: 11549113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
